Defactinib (dual FAK and PYK2 inhibitor) is a clinically utilized drug that has been shown to have potential in models of chronic lymphocytic leukemia in vitro [49]. This evidence concerns the gene PTK2 and B-cell chronic lymphocytic leukemia.